Soligenix Reports Positive Extended Phase 2a Results for Psoriasis Treatment SGX302

Soligenix Inc. reported extended results from its ongoing Phase 2a trial evaluating SGX302 for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel demonstrated improvements across multiple clinical and quality-of-life measures, with results comparable to or exceeding those observed with the prior ointment formulation. This development supports continued advancement of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis patients.

The extended Phase 2a results showed the SGX302 gel was well tolerated with no drug-related adverse events reported. Clinical improvements were measured using standard assessment tools including Investigator Global Assessment and Psoriasis Area and Severity Index scores. These positive outcomes from the additional cohort treated with the optimized gel formulation provide important validation for the drug's development pathway. The company's focus on rare diseases with unmet medical needs positions this psoriasis treatment as a potentially significant advancement in dermatological care.

Soligenix's Specialized BioTherapeutics business segment is developing synthetic hypericin-based therapies, with SGX302 representing an expansion into psoriasis treatment. The company's broader development pipeline includes HyBryte for cutaneous T-cell lymphoma, which has completed Phase 3 studies, and other programs targeting inflammatory diseases. The successful extension of the Phase 2a trial results strengthens the scientific foundation for SGX302's continued development and potential future regulatory submissions.

The implications of these extended results are significant for both patients and the pharmaceutical industry. Psoriasis affects millions worldwide, and current treatments often come with safety concerns or limited efficacy. A non-carcinogenic, non-mutagenic topical treatment like SGX302 could address important unmet needs in psoriasis management. The positive safety profile observed in the extended trial results suggests potential advantages over existing therapies that may carry carcinogenic risks or other significant side effects.

For the biopharmaceutical industry, Soligenix's progress with SGX302 demonstrates the potential of synthetic hypericin technology across multiple therapeutic areas. The company's approach to rare disease treatment development, combined with their Public Health Solutions business segment focusing on vaccine candidates, shows a diversified strategy for addressing significant medical challenges. Continued positive results from clinical trials like this Phase 2a extension could accelerate development timelines and increase the treatment's commercial potential.

Investors and industry observers can find additional information about Soligenix's developments through the company's newsroom at https://nnw.fm/SNGX. The broader context of these results within Soligenix's portfolio suggests strategic positioning in both specialized therapeutics and public health solutions, with government support from agencies including the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority for their vaccine programs.